You are here

Ciclopirox Olamine Cream Approved

HAWTHORNE, N.Y.--(BUSINESS WIRE)--April 14, 2005-- Taro Pharmaceutical Industries Ltd. (NASDAQ: TARO - News) reported today that Taro Pharmaceuticals U.S.A., Inc. has received approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Ciclopirox Olamine Cream USP, 0.77% ("ciclopirox cream").

Taro's ciclopirox cream is a prescription pharmaceutical product used for the treatment of fungal infections of the skin. The Taro product is bioequivalent to Medicis Pharmaceutical Corp.'s Loprox® Topical Cream. According to industry sources, ciclopirox cream products had U.S. sales of approximately $32.5 million in 2004.

Source: Taro Pharmaceutical Industries, Inc.

Recent Headlines

Potential contamination could lead to supply chain disruptions
Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs